Vivos (RDGL) Change in Accured Expenses (2010 - 2025)
Vivos (RDGL) reported Change in Accured Expenses of -$20221.0 for Q4 2025, down 154.08% on a YoY basis from $37389.0 in Q4 2024, and down 224.55% sequentially from $16235.0 in Q3 2025.
Vivos (RDGL) Change in Accured Expenses (2010 - 2025) Analysis & Trends
Vivos (RDGL) has 16 years of Change in Accured Expenses data on file, last reported at -$20221.0 in Q4 2025.
- For the quarter ending Q4 2025, Change in Accured Expenses fell 154.08% year-over-year to -$20221.0; the trailing twelve-month figure through Dec 2025 stood at $6263.0 (up 103.94% YoY), and the FY2025 full-year result was $6263.0, up 103.94% from the prior year.
- Change in Accured Expenses slipped to -$20221.0 in Q4 2025, from $16235.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $176085.0 in Q4 2023 to a low of -$170238.0 in Q1 2024.
- A 5-year average of $4115.8 and a median of $839.5 in 2021 frame the typical range for Change in Accured Expenses.
- Peak annual rise in Change in Accured Expenses reached 1261.2% in 2022, while the deepest fall reached 768.76% in 2022.
- Tracing RDGL's Change in Accured Expenses over 5 years: stood at $11852.0 in 2021, then tumbled by 768.76% to -$79261.0 in 2022, then jumped by 322.16% to $176085.0 in 2023, then tumbled by 78.77% to $37389.0 in 2024, then plunged by 154.08% to -$20221.0 in 2025.
- Business Quant data shows RDGL's Change in Accured Expenses at -$20221.0 in Q4 2025, $16235.0 in Q3 2025, and -$18920.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.38 Bn | 176.08 Bn | 6.27 Bn | - |
| 2 | Stryker | 129.56 Bn | 126.68 Bn | 3.81 Bn | -654.00 Mn |
| 3 | Medtronic | 109.00 Bn | 99.78 Bn | 6.41 Bn | 123.00 Mn |
| 4 | Boston Scientific | 68.59 Bn | 67.13 Bn | 3.61 Bn | -512.00 Mn |
| 5 | Edwards Lifesciences | 47.58 Bn | 43.90 Bn | 1.29 Bn | -347.10 Mn |
| 6 | Dexcom | 28.65 Bn | 27.53 Bn | 750.30 Mn | 145.10 Mn |
| 7 | GE HealthCare Technologies | 28.55 Bn | 26.27 Bn | 1.98 Bn | -250.00 Mn |
| 8 | Smith & Nephew | 27.05 Bn | 26.48 Bn | - | - |
| 9 | Koninklijke Philips | 25.59 Bn | 22.46 Bn | 2.07 Bn | 21.07 Mn |
| 10 | Vivos | 27.57 Mn | 26.01 Mn | -3,105.00 | -20,221.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -20,221.00 |
| Dec 31, 2025 | -20,221.00 |
| Sep 30, 2025 | 16,235.00 |
| Sep 30, 2025 | 16,235.00 |
| Jun 30, 2025 | -18,920.00 |
| Jun 30, 2025 | -18,920.00 |
| Mar 31, 2025 | 29,169.00 |
| Mar 31, 2025 | 29,169.00 |
| Dec 31, 2024 | 37,389.00 |
| Dec 31, 2024 | 37,389.00 |
| Sep 30, 2024 | -117,740.00 |
| Sep 30, 2024 | -117,740.00 |
| Jun 30, 2024 | 91,794.00 |
| Jun 30, 2024 | 91,794.00 |
| Mar 31, 2024 | -170,238.00 |
| Mar 31, 2024 | -170,238.00 |
| Dec 31, 2023 | 176,085.00 |
| Dec 31, 2023 | 176,085.00 |
| Sep 30, 2023 | -15,441.00 |
| Sep 30, 2023 | -15,441.00 |